Study: Pfizer lung cancer pill may double survival - WIS News 10 - Columbia, South Carolina |
By LINDA A. JOHNSON
AP Business Writer
TRENTON, N.J. (AP) - A much-anticipated drug for advanced lung cancer from Pfizer Inc. appears to double survival over standard drugs against tumors with a certain genetic mutation, according to research presented Sunday.
The drug, called crizotinib, would be the first targeted treatment for the roughly 50,000 people who get this cancer each year worldwide. It might eventually produce annual revenue for Pfizer exceeding $2 billion.
The first overall survival data for patients with advanced non-small cell lung cancer treated with the drug, called crizotinib, showed 74 percent were still alive after a year and 54 percent after two years, researchers announced at a huge cancer specialists conference.
Median overall survival, a key measure, hasn't been determined because more than half the 82 patients are still alive.
Read more.
10 comments:
Pfizer unveiled data that demonstrated the lung drug, which is tailored to treat the 3% to 5% of patients with ALK-positive cases, doubled survival time compared with average survival rates.
A searchable database of prescription drugs for lung diseases or respiratory conditions from the Canadian Lung Association.
Pfizer had presented initial results from the crizotinib study at last year's ASCO meeting, but they didn't include overall survival data.
If you breathe radon in, it can change the cells in your lungs. These changes can increase your chances for getting lung cancer.
Lung cancer is one of the most common types of cancer in the developed world.There is a rare type of cancer that affects the lining of the lung or the abdomen and is called mesothelioma.Mesothelioma in the lungs is often caused by exposure to the insulating material asbestos and it is very different to lung cancer.
Smoking affects lung and causes lung cancer. Its harmful effects do not end there. Cancer and some other illness such as heart diseases, stroke and other cardiovascular diseases are caused by the act.
Ya I am fully agree with your opinion.
I am giving you all marks for this post.Really great stuff by author.thanks.
The first overall survival data for patients with advanced non-small cell lung cancer treated with the drug, called crizotinib, showed 74 percent were still alive after a year and 54 percent after two years, researchers announced at a huge cancer specialists conference.
Go for Pfizer products as they have great aims and their products are also great! Thanks a lot and more power to Pfizer!
Post a Comment